Vaxcyte, Inc.
PCVX
Peringkat dalam Saham
#2061
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Harga Saham
$64.17
Kapitalisasi Pasar
$10.10B
Perubahan (1 hari)
-3.11%
Perubahan (1 tahun)
51.52%
Negara
US
Perdagangan Vaxcyte, Inc. (PCVX)
Kategori
Healthcare
Riwayat harga saham Vaxcyte, Inc. (PCVX)
Harga penutupan tertinggi: $65.63 pada 2026-10-01
Harga penutupan terendah: $32.16 pada 2020-06-01
Harga penutupan terendah: $32.16 pada 2020-06-01
Riwayat harga saham Vaxcyte, Inc. dari 2020 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2026 (TTM) | 18.84% |
| 2025 | -48.18% |
| 2024 | 49.19% |
| 2023 | 30.50% |
| 2022 | 103.95% |
| 2021 | -26.14% |
| 2020 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $525.41 | 23.26% |
US
|
|
| $252.59 | 818.83% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $887.75 | 6.35% |
NL
|
|
| $752.87 | 7.40% |
CH
|
